Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for Carcinoma, Hepatocellular
This study is evaluating whether a new type of MRI scan may be useful for detecting liver cancer.
See full descriptionAbout the trial for Carcinoma, Hepatocellular
Treatment Groups
This trial involves 2 different treatments. Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid will improve 2 primary outcomes in patients with Carcinoma, Hepatocellular. Measurement will happen over the course of up to 12 months from completion of imaging.
Who is running the study
Principal InvestigatorPatient Q & A Section
What are the signs of carcinoma, hepatocellular?
Cirrhosis is a sign of cirrhosis and is usually a result of chronic alcoholism. Signs associated with liver cirrhosis include abdominal swelling, ascites, dark urine, hepatic encephalopathy, abdominal pain, or jaundice. Other nonspecific signs may include muscle tenderness, ascites, edema or swelling of the ankles due to pleural fluid, enlarged liver and enlarged spleen. Other nonspecific signs associated with liver cancer include itching, fever and weight loss.\n
What is carcinoma, hepatocellular?
There is a great deal of variability in clinical characteristics of this carcinoma; therefore, diagnostic accuracy is a significant issue. Although metastatic hepatocellular carcinoma has been previously considered a rare event, we have demonstrated a growing spectrum of disease presentation that has significant clinical management ramifications.
What causes carcinoma, hepatocellular?
In contrast to the current hypotheses, this study suggests that there is no association between liver cirrhosis and hepatocellular carcinoma, in the Taiwanese Taiwanese population.
What are common treatments for carcinoma, hepatocellular?
Common treatment for carcinoma, hepatocellular includes: surgery, radiotherapy, chemotherapy, embolization and biotherapy. There are no curative treatments for carcinoma, hepatocellular, so physicians seek to achieve long-term survival.
What is the primary cause of carcinoma, hepatocellular?
Based on this study, carcinoma, hepatocellular is primarily a disease of older persons, with an incidence of 7.5 per 100,000 person-years for females and 7.8 per 100,000 for males. On average, the likelihood of an occurrence for a given age group can be calculated as the log-normal distribution. The cumulative probability of carcinoma, hepatocellular occurring during the lifetime of a person whose age is 65 years is 0.719; this calculation implies that 0.719 X (0.716 - 0.719) = 73.78% chance of occurrence.
How serious can carcinoma, hepatocellular be?
A meta-regression analysis showed that liver cancer has 2-fold or higher risk of developing malignant neoplasm, and the proportion of advanced stage HCC is 20-30% higher in the metastasis group than the non-metastasis group.
What is the average age someone gets carcinoma, hepatocellular?
[Carcinoma, hepatocellular, at all ages is similar in incidence at (1.0-4.5 yr). A gradual and inverse association of this cancer with increasing age is observed in Caucasians, but in the Black population, the incidence of carcinoma, hepatocellular, increases. (Black: 1.1 yr vs. Black: 0.7 yr; p > 0.05; White: 1.9 yr vs. White: 0.7 yr; p > 0.
How quickly does carcinoma, hepatocellular spread?
The extent of tumour infiltration and metastasis to liver at the time of CCLM diagnosis are important prognostic factors that can be used to stratify prognostic risk groups in patients with hepatocellular carcinoma undergoing curative treatment.
What are the chances of developing carcinoma, hepatocellular?
It is important to recognize the signs and symptoms of liver disease that can help identify patients at an increased risk of developing malignant disease. In addition, clinicians should remember that even though the presence of atypical symptoms (i.e. fatigue, dizziness, jaundice) may hint towards a possible diagnosis, liver cancer can also present with these atypical symptoms.
What is the survival rate for carcinoma, hepatocellular?
In the present study, an overall 5-year survival rate for HCC was 46%. The prognosis (especially the prognosis of the curative hepatectomy) was slightly different between patient groups with and without cirrhosis. Thus, the resection of the liver may prevent cirrhosis progression to HCC.